Ei­sai projects $7B in sales by 2030 for new Alzheimer's drug

Ei­sai and Bio­gen’s new­ly ap­proved Alzheimer’s drug Leqem­bi (lecanemab) is look­ing to do what its amy­loid-tar­get­ed pre­de­ces­sor, Bio­gen’s Aduhelm (ad­u­canum­ab), has yet to ac­com­plish — hit block­buster sta­tus.

In a press con­fer­ence yes­ter­day, Ei­sai ex­ecs pro­ject­ed $7 bil­lion (1 tril­lion yen) in Leqem­bi world­wide sales by 2030, as­sum­ing broad­er cov­er­age from CMS, which has so far lim­it­ed the use of any amy­loid-tar­get­ed Alzheimer’s drugs to clin­i­cal tri­als. The $7 bil­lion es­ti­mate is based on the com­pa­ny’s es­ti­mate that about 2.5 mil­lion peo­ple will be el­i­gi­ble for treat­ment by 2030, with preva­lence in Asia/Latin Amer­i­ca and Chi­na po­ten­tial­ly reach­ing 70% of the glob­al to­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER